Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 603 All time
- Disclosed funding
- $28.7B 480 disclosed amounts
- Median round
- $17M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| NB Neela BiotechCompany profile Neela Biotech develops microbial processes that turn organic waste into feedstocks for sustainable aviation fuel. Neela Biotech develops microbial processes that turn organic waste into feedstocks for sustainable aviation fuel. | Undisclosed | Growth Catalyst grantUndisclosed | Biotech, Climate tech | United Kingdom | Investors | |
| CN Coherence NeuroCompany profile Investigational implants and bioelectronic systems for monitoring and treating cancer. Investigational implants and bioelectronic systems for monitoring and treating cancer. | $10M | Seed | Biotech, Healthtech | United States | Investors | |
Kailera TherapeuticsCompany profile Kailera Therapeutics develops oral and injectable medicines for obesity using several GLP-1-based mechanisms. Kailera Therapeutics develops oral and injectable medicines for obesity using several GLP-1-based mechanisms. | $600M | Series B | Biotech | United States | Investors | |
KardiganCompany profile Kardigan develops cardiovascular medicines that target specific biological drivers of heart disease and the patient groups most likely to respond. Kardigan develops cardiovascular medicines that target specific biological drivers of heart disease and the patient groups most likely to respond. | $254M | Series B | Biotech | United States | Investors | |
| SB Surv BioPharma develops oncolytic virus therapies for cancer. | ¥1.5B | Series B first closeSeries B | Biotech | Japan | Investors | |
| F FELIQS develops small-molecule medicines for retinal diseases. | $10M | Series A total including extensionSeries A | Biotech | Japan | Investors | |
| A AmytisCompany profile Amytis builds an AI-assisted workspace for life science researchers, connecting experiment planning, laboratory records, literature and data analysis. Amytis builds an AI-assisted workspace for life science researchers, connecting experiment planning, laboratory records, literature and data analysis. | £60K | Accelerator investmentUndisclosed | Biotech, Enterprise software | United Kingdom | Investors | |
| T Saliva-based diagnostics that measure a person’s circadian rhythm. | Undisclosed | capacura investmentUndisclosed | Biotech, Healthtech | Germany | Investors | |
Beeline MedicinesCompany profile Beeline Medicines develops clinical-stage therapies that target immune dysfunction in lupus and other autoimmune and inflammatory diseases. Beeline Medicines develops clinical-stage therapies that target immune dysfunction in lupus and other autoimmune and inflammatory diseases. | $300M | Series A | Biotech | United States | Investors | |
LABTECHSCompany profile LABTECHS develops rapid sterility testing kits and reagents from research at the University of Toyama. LABTECHS develops rapid sterility testing kits and reagents from research at the University of Toyama. | Undisclosed | Go-Tech research grant selectionUndisclosed | Biotech | Japan | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Delix Therapeutics, Alethio Therapeutics, Estuary Biotherapeutics
27rounds6led - 2Eli Lilly and Company
Oyster Therapeutics, BigHat Biosciences, Circle Pharma, Inc.
16rounds0led - 3Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
16rounds1led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
16rounds1led - 5OrbiMed
Dren Bio, Star Therapeutics, Leal Therapeutics
12rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.